dabigatran
Pradaxa (dabigatran etexilate) is an oral direct thrombin inhibitor from Boehringer Ingelheim. By blocking thrombin, the enzyme that forms clots, it reduces stroke risk in atrial fibrillation and treats or prevents deep vein thrombosis and pulmonary embolism.
This page is based on FDA prescribing information and the EMA medicine record for dabigatran, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Building a blood clot is like weaving a net, and thrombin is the loom that spins the final threads. Dabigatran sits directly on the loom and stops it weaving, so the net never forms - and unlike some older medicines it needs no helper to do the job.
In simple terms
When a clot forms, an enzyme called thrombin turns soluble proteins into the sticky fibrin mesh that holds the clot together. Dabigatran binds thrombin itself and blocks its activity, whether thrombin is floating in the blood or already attached to a clot. This prevents clots from forming or growing, which protects against stroke in atrial fibrillation and treats clots in the legs and lungs.
In depth
Dabigatran etexilate is an oral prodrug converted by esterases to dabigatran, a competitive, reversible direct thrombin inhibitor. It binds the active site of both free and clot-bound thrombin, blocking fibrinogen cleavage, thrombin-mediated platelet activation and amplification of the coagulation cascade. Unlike heparins it does not require antithrombin as a cofactor, and its predictable pharmacokinetics allow fixed dosing without routine coagulation monitoring.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How direct thrombin inhibitors prevent clots
- Thrombin is the enzyme that turns fibrinogen into the fibrin threads of a clot.
- Dabigatran sits directly on thrombin's active site and blocks it, with no helper protein needed.
- It blocks thrombin whether that enzyme is floating in the blood or already attached to a clot, so fibrin threads cannot form and the clot cannot grow.
- The risk of new clots in veins or arteries falls.
Target: Thrombin
The enzyme that converts fibrinogen into fibrin, the mesh that holds a clot together; it also amplifies clotting and activates platelets, so blocking it halts clot formation at its core.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To reduce the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation
- Treatment of deep vein thrombosis and pulmonary embolism in adults who have been treated with a parenteral anticoagulant for 5 to 10 days
- To reduce the risk of recurrence of deep vein thrombosis and pulmonary embolism in adults who have been previously treated
Approved uses in European Union
EMA- Primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement or total knee replacement surgery
- Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors
- Treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism, in adults
Official sources
The statements on this page trace back to these records.
- U.S. Food and Drug Administration: dabigatran etexilate prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: dabigatran etexilate mesylate
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.